What is Qnexa? The name Qnexa is the title for a new weight loss drug from the company Vivus, Inc.. Vivus is a phameceutical company that is focused on developing and designing remedies to that specifically address obesity, sleep apnea, diabetes, and the sexual health of males. This particular drug is a combination of two different chemicals that have already received approval by the United States Food and Drug Administration. The Vivus product is targeted at an estimated 78 million Americans that are currently fighting obesity in the United States of America. In addition, the product will also be marketed as a potential worldwide solution to obesity, as there are an estimated 500 million people that are obese.
The Qnexa product is a combination of phentermine and topiramete that are administered through a time-release capsule. The FDA has previously approved both phentermine and topiramete, but not in the combination used in Qnexa.
Qnexa FDA Aproval: Vivus resubmitted the application for the product on October 17th, 2011. Vivus proposes that Qnexa be made available for the treatment of obesity in adults with a Body Mass Index BMI of grater than 30 kg/m2, and for overweight patients with a BMI greater than 27 kg/m2 with a history of type of conditions such as 2 diabetes, central adiposity, dyslipemia, or hypertension. In an overwhelming decision of 20 to 2, an FDA advisory committee recommended the approval of the Qnexa drug. While this does not constitute an official FDA approval for the product, the FDA generally follows the recommendations set forth by the advisory committee.
It is important to note that the FDA advisory committee reversed its 2010 recommendation against the approval of the drug. The advisory committee recommends that certain precautions and regulations be considered and put in place. The FDA is expected to make an official approval decision of Qnexa by April 17th, 2012.
Qnexa Side Effects: There are potential side effects that critics of the Vivus, Inc. product have raised concerns about. The Qnexa side effects commonly found include tingling, dry mouth, constipation, altered taste, insomnia, dizziness, upper repertory infection, sinus infection, and runny nose. There are potentially dangerous side effects associated with Qnexa that include increased heart rates, arrhythmias, and hearts in patients taking the Vivus product.
Conclusion: In conclusion, time will only tell whether the FDA will officially approve Qnexa on April 17th, 2012. If you would like to read and find more information on the Qnexa product and Vivus Inc., there are three published clinical studies that can give additional insights. The three clinical studies conducted are titled the EQUIP Study, CONQUER Study, and Sequel Study.
This article is focused on the new Vivus inc. product Qnexa. The QnexaFacts team is dedicated towards making the http://www.QnexaFacts.com website, the #1 website on Qnexa and Vivus information.
If you have any questions or requests for additional content from Qnexa Facts, please email our team directly at Team@QnexaFacts.com, or visit or new website at http://www.QnexaFacts.com.
Article Source:http://EzineArticles.com/?expert=Charles_B_Wilson
Did you find this article helpful?00
Get Involved0 commentsSuggest a topicArticle ToolsPrint this articleE-mail to a friendEzinePublisherReport this articleCite this articleStay InformedGet notified by email when new articles are added to this category or written by this author.Subscribe to New Article Alerts: Health and Fitness: Medicine
Charles B Wilson
Medicine Article FeedFind More ArticlesSearchRecent ArticlesIntroduction To Post-Marketing Pharmacovigilance For New Drugs5 Benefits Of Medical Transcription WorkPost-Marketing Pharmacovigilance For Well-Established DrugsIntroduction To Clinical TrialsCritical Skills Required If You Plan To Work As A Medical TranscriptionistThe Physician - Ambition And LearningPeripheral Facial Palsy (Bell's Palsy)Understanding the Medical Side Effects Vicodin UseThe Best Pharmaceutical Testing LabsWhat You Need to Know About Robotic Heart SurgerySubmitted On February 25, 2012. Viewed 12 times. Word count: 440.MLA Style Citation:Wilson, Charles B.".".25 Feb. 2012EzineArticles.com.8 Apr. 2012
Wilson, C. B. (2012, February 25). . Retrieved April 8, 2012, from http://ezinearticles.com/?What-Is-the-Vivus-Inc.-Answer-to-Obesity?&id=6904407Chicago Style Citation:
Wilson, Charles B. "." EzineArticles.com. http://ezinearticles.com/?What-Is-the-Vivus-Inc.-Answer-to-Obesity?&id=6904407
EzineArticles.com© 2012 EzineArticles.comAll Rights Reserved WorldwideAbout UsFAQContact UsMember BenefitsPrivacy PolicyShopSite MapBlogTrainingVideo ArchiveAdvertisingAffiliatesCartoonsAuthorsSubmit ArticlesMembers LoginPremium MembershipExpert AuthorsEndorsementsEditorial GuidelinesTerms of ServicePublishersFollow UsTerms Of ServiceEzines / Email AlertsManage SubscriptionsEzineArticles RSS
View the Original article
0 comments:
Post a Comment